41049-91-6

Basic information

• Product Name: 2-(p-nitrophenyl)ethyl p-nitrobenzenesulphonate
• Synonyms: 2-(p-nitrophenyl)ethyl p-nitrobenzenesulphonate
• CAS NO: 41049-91-6
• Molecular Weight: 352.324
• Mol File: 41049-91-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-(p-nitrophenyl)ethyl p-nitrobenzenesulphonate(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(p-nitrophenyl)ethyl p-nitrobenzenesulphonate(41049-91-6)
• EPA Substance Registry System: 2-(p-nitrophenyl)ethyl p-nitrobenzenesulphonate(41049-91-6)

Safety Data

• Hazardous Substances Data: 41049-91-6(Hazardous Substances Data)

Upstream product

• 100-27-6 2-(4-nitrophenyl)ethanol 
• 98-74-8 4-Nitrobenzenesulfonyl chloride 

Downstream Products

• 1253582-45-4 5-[(R)-2-{benzyl-[2-(4-nitrophenyl)ethyl]amino}-1-(tert-butyldimethylsilanyloxy)ethyl]-8-benzyloxy-1H-quinolin-2-one 
• 1253582-47-6 biphenyl-2-ylcarbamic acid 1-[2-({3-[4-(2-{benzyl-[(R)-2-(8-benzyloxy-2-oxo-1,2-dihydroquinolin-5-yl)-2-(tert-butyldimethylsilanyloxy)ethyl]-amino}ethyl)phenylcarbamoyl]phenyl}methylcarbamoyl)ethyl]piperidin-4-yl ester 
• 1253582-48-7 biphenyl-2-ylcarbamic acid 1-(2-{[3-(4-{2-[(R)-2-(tert-butyldimethylsilanyloxy)-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]-ethyl}phenylcarbamoyl)phenyl]methylcarbamoyl}ethyl)piperidin-4-yl ester 
• 1253580-13-0 biphenyl-2-ylcarbamic acid 1-(2-{[3-(4-{2-[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]ethyl}phenylcarbamoyl)-phenyl]methylcarbamoyl}ethyl)piperidin-4-yl ester 
• 1253582-46-5 5-[(R)-2-{[2-(4-aminophenyl)ethyl]benzylamino}-1-(tert-butyldimethylsilanyloxy)ethyl]-8-benzyloxy-1H-quinolin-2-one 
• 138-42-1 p-nitrobenzenesulfonic acid 
• 841-19-0 N-phenyl-4-nitrophenethylamine 
• 19904-92-8 4-methoxy-N-(4-nitrophenethyl)aniline 
• 37043-94-0 N-(4-nitro-phenethyl)-p-toluidine 

Relevant articles and documents

DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

This invention relates to a compound of formula I; or a pharmaceutically acceptable salt thereof. Such compounds possess both muscarinic receptor antagonist and β2 adrenergic receptor agonist activities. The invention also relates to pharmaceutical compositions comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compounds as bronchodilating agents to treat pulmonary disorders.